Long-Term Financial, Psychosocial, and Overall Health-Related Quality of Life After Living Liver Donation.


Journal

The Journal of surgical research
ISSN: 1095-8673
Titre abrégé: J Surg Res
Pays: United States
ID NLM: 0376340

Informations de publication

Date de publication:
09 2020
Historique:
received: 30 01 2020
revised: 13 03 2020
accepted: 16 03 2020
pubmed: 23 4 2020
medline: 28 10 2020
entrez: 23 4 2020
Statut: ppublish

Résumé

To assess the impact of living liver donation (LD) in a diverse and aging population up to 20 y after donation, particularly with regard to medical, financial, psychosocial, and overall health-related quality of life (HRQOL). Patients undergoing LD between 1999 and 2009 were recruited to respond to the Short-Form 36 and a novel Donor Quality of Life Survey at two time points (2010 and 2018). Sixty-eight living liver donors (LLDs) completed validated surveys, with a mean follow-up of 11.5 ± 5.1 y. Per Donor Quality of Life Survey data, physical activity or strength was not impacted by LD in most patients. All respondents returned to school or employment, and 82.4% reported that LD had no impact on school or work performance. LD did not impact health insurability in 95.6% of donors, and only one patient experienced difficulty obtaining life insurance. Overall, 97.1% of respondents did not regret LD. Short-Form 36 survey-measured outcomes were similar between LLDs and the general U.S. LLDs who responded in both 2010 and 2018 were followed for an overall average of 15.4 ± 2.4 y and HRQOL outcomes in these donors also remained statistically equivalent to U.S. population norms. This study represents the longest postdonation follow-up and offers unique insight related to HRQOL in a highly diverse patient population. Although LLDs continue to maintain excellent HRQOL outcomes up to 20 y after donation, continued lifetime follow-up is required to accurately provide young, healthy potential donors with an accurate description of the risks that they may incur on aging.

Sections du résumé

BACKGROUND
To assess the impact of living liver donation (LD) in a diverse and aging population up to 20 y after donation, particularly with regard to medical, financial, psychosocial, and overall health-related quality of life (HRQOL).
METHODS
Patients undergoing LD between 1999 and 2009 were recruited to respond to the Short-Form 36 and a novel Donor Quality of Life Survey at two time points (2010 and 2018).
RESULTS
Sixty-eight living liver donors (LLDs) completed validated surveys, with a mean follow-up of 11.5 ± 5.1 y. Per Donor Quality of Life Survey data, physical activity or strength was not impacted by LD in most patients. All respondents returned to school or employment, and 82.4% reported that LD had no impact on school or work performance. LD did not impact health insurability in 95.6% of donors, and only one patient experienced difficulty obtaining life insurance. Overall, 97.1% of respondents did not regret LD. Short-Form 36 survey-measured outcomes were similar between LLDs and the general U.S.
POPULATION
LLDs who responded in both 2010 and 2018 were followed for an overall average of 15.4 ± 2.4 y and HRQOL outcomes in these donors also remained statistically equivalent to U.S. population norms.
CONCLUSIONS
This study represents the longest postdonation follow-up and offers unique insight related to HRQOL in a highly diverse patient population. Although LLDs continue to maintain excellent HRQOL outcomes up to 20 y after donation, continued lifetime follow-up is required to accurately provide young, healthy potential donors with an accurate description of the risks that they may incur on aging.

Identifiants

pubmed: 32320896
pii: S0022-4804(20)30147-5
doi: 10.1016/j.jss.2020.03.025
pmc: PMC8351216
mid: NIHMS1729921
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

41-52

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL141857
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000130
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001855
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

Am J Transplant. 2019 Feb;19 Suppl 2:184-283
pubmed: 30811890
Liver Transpl. 2013 May;19(5):499-506
pubmed: 23172840
Hepatobiliary Surg Nutr. 2016 Apr;5(2):133-40
pubmed: 27115007
Liver Transpl. 2015 Aug;21(8):1082-90
pubmed: 25991054
Annu Rev Med. 2019 Jan 27;70:225-238
pubmed: 30355261
Transplantation. 2007 Jun 15;83(11):1506-8
pubmed: 17565325
Liver Transpl. 2007 Jun;13(6):886-95
pubmed: 17539009
Liver Transpl. 2010 May;16(5):649-57
pubmed: 20440774
Hepatology. 2011 Oct;54(4):1313-21
pubmed: 21688284
Transplant Proc. 2008 Apr;40(3):720-1
pubmed: 18454997
Liver Transpl. 2010 Dec;16(12):1352-8
pubmed: 21117194
Transplantation. 2002 May 27;73(10):1593-7
pubmed: 12042645
Ann Transplant. 2019 Jan 22;24:45-51
pubmed: 30666044
JAMA Surg. 2014 Mar;149(3):288-91
pubmed: 24452612
Transplantation. 1998 Nov 27;66(10):1313-6
pubmed: 9846514
Liver Transpl. 2013 May;19(5):472-81
pubmed: 23447523
Transplantation. 2018 Jan;102(1):105-118
pubmed: 28885494
Am J Transplant. 2010 Feb;10(2):364-71
pubmed: 20415904
Am J Transplant. 2012 May;12(5):1208-17
pubmed: 22335782
Transplantation. 2016 Jun;100(6):1251-6
pubmed: 27203592
Liver Transpl. 2019 May;25(5):724-733
pubmed: 30589993
J Bone Joint Surg Am. 2015 Oct 7;97(19):1628-34
pubmed: 26446970
Liver Transpl. 2016 Jan;22(1):53-62
pubmed: 26332078
Gastroenterology. 2012 Feb;142(2):273-80
pubmed: 22108193
Transplantation. 2016 Jun;100(6):1257-69
pubmed: 27152918
Ann Surg. 2015 Sep;262(3):465-75; discussion 473-5
pubmed: 26258315
Am J Transplant. 2011 Jan;11(1):101-10
pubmed: 21199351
Health Qual Life Outcomes. 2007 Sep 07;5:54
pubmed: 17825096
J Hepatol. 2015 Feb;62(2):346-53
pubmed: 25195558
J Clin Epidemiol. 1998 Nov;51(11):903-12
pubmed: 9817107
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Transplant Proc. 2010 Dec;42(10):4449-54
pubmed: 21168716
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):373-382
pubmed: 28196987
Gastroenterology. 2008 Aug;135(2):468-76
pubmed: 18505689
Lancet. 2003 Aug 30;362(9385):687-90
pubmed: 12957090
Liver Transpl. 2012 Nov;18(11):1343-52
pubmed: 22821503
J Gastrointestin Liver Dis. 2018 Jun;27(2):169-178
pubmed: 29922762
Am J Transplant. 2009 May;9(5):1169-78
pubmed: 19422341
Am J Transplant. 2014 Feb;14(2):367-74
pubmed: 24472194
Transplantation. 2009 Jul 15;88(1):110-4
pubmed: 19584689

Auteurs

Muhammad H Raza (MH)

Keck School of Medicine, University of Southern California, Los Angeles, California.

Michelle H Kim (MH)

Keck School of Medicine, University of Southern California, Los Angeles, California; Division of Hepatobiliary and Abdominal Transplant Surgery, Department of Surgery, University of Southern California, Los Angeles, California.

Li Ding (L)

Department of Preventive Medicine, University of Southern California, Los Angeles, California.

Tse-Ling Fong (TL)

Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, California.

Christian Romero (C)

Department of Surgery, University of Southern California, Los Angeles, California.

Yuri Genyk (Y)

Keck School of Medicine, University of Southern California, Los Angeles, California; Division of Hepatobiliary and Abdominal Transplant Surgery, Department of Surgery, University of Southern California, Los Angeles, California.

Linda Sher (L)

Keck School of Medicine, University of Southern California, Los Angeles, California; Division of Hepatobiliary and Abdominal Transplant Surgery, Department of Surgery, University of Southern California, Los Angeles, California.

Juliet Emamaullee (J)

Keck School of Medicine, University of Southern California, Los Angeles, California; Division of Hepatobiliary and Abdominal Transplant Surgery, Department of Surgery, University of Southern California, Los Angeles, California. Electronic address: Juliet.emamaullee@med.usc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH